BioSpace News Archive

The company reported its results for the second quarter ended September 30, 2017.

New personnel leading the Scientist.com European expansion include Tom Dexter, VP Business Development (UK); Christoph Schittny, VP Strategic Partnerships (Germany); Laura Benitez, PhD, Sr. Director Business Development (Spain); Mark Livingstone, PhD, Account Manager (France); and Sarah Harkcom, General Counsel (UK).

Under the Prescription Drug User Fee Act, the FDA has set an action date of June 23, 2018.

Compugen today announced that it is advancing COM902, its lead anti-TIGIT antibody, into manufacturing in anticipation of filing an IND in 2019.

The company announced that Benign Prostatic Hyperplasia treatments utilizing TULSA-PRO® are now being successfully conducted in Germany.

Under the agreement, Huahai takes a $30M equity stake in Eutilex and receives an exclusive license to develop and commercialize EU-101.

Massachusetts General Hospital and Brigham and Women’s Hospital have chosen to adopt this new technology.

BPN14770 is a highly selective inhibitor of PDE4D, which regulates brain signaling pathways involved in the early and late stages of memory formation.

This clinical trial marks the next stage in the company’s ongoing commitment to address the significant unmet needs of patients diagnosed with this devastating disease and it is the company’s third clinical trial initiated in 2017.

Natera today announced a second research collaboration with Denmark’s Aarhus University utilizing the company’s Signatera technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients.